This technology utilizes mastic gum, a resin from the Mediterranean mastic tree, as an active ingredient in pharmaceutical compositions and health supplements for the prevention and treatment of influenza A virus infections. The composition inhibits infection by blocking the stage where the virus enters host cells.
Current treatments like neuraminidase inhibitors (e.g., oseltamivir) and M2 ion channel inhibitors (e.g., amantadine, rimantadine) target viral replication. However, frequent antigenic mutations have led to an increase in drug-resistant viruses. Furthermore, these treatments require oral or intravenous administration, must be taken within 48 hours of symptom onset, and are associated with side effects like nausea and headaches, creating a need for safe, natural alternatives.
By inhibiting the phosphorylation of the MAPK signaling pathway activated during viral infection, this technology blocks the virus from entering cells entirely. Because its mechanism differs from existing drugs that target replication enzymes, it remains effective against resistant strains. Designed for direct nasal administration, it acts rapidly against influenza A-related conditions such as the flu, pharyngitis, bronchitis, pneumonia, and sepsis. It can be applied to nasal spray flu preventatives, adjunctive therapies for Tamiflu-resistant patients, and respiratory health supplements, enabling the creation of natural antiviral products that block infection at the nasal mucosa, the virus's primary entry point.
N/A
